GW Pharmaceuticals PLC closed the most recent trading day at $119.53, moving -1.1% from the previous trading session. This change was narrower than the S&P 500's 1.91% loss on the day. Meanwhile, the Dow lost 2.02%, and the Nasdaq, a tech-heavy index, lost 2.26%.
Heading into today, shares of the company had lost 7.27% over the past month, lagging the Medical sector's gain of 0.32% and the S&P 500's loss of 2.51% in that time.
GWPH will be looking to display strength as it nears its next earnings release, which is expected to be February 4, 2019. The company is expected to report EPS of -$2.82, down 16.05% from the prior-year quarter. Our most recent consensus estimate is calling for quarterly revenue of $13.30 million, up 72.06% from the year-ago period.
GWPH's full-year Zacks Consensus Estimates are calling for earnings of -$9.41 per share and revenue of $115.39 million. These results would represent year-over-year changes of +10.89% and +580.53%, respectively.
Investors might also notice recent changes to analyst estimates for GWPH. These revisions help to show the ever-changing nature of near-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the company's business outlook.
Our research shows that these estimate changes are directly correlated with near-term stock prices. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Within the past 30 days, our consensus EPS projection has moved 39.47% lower. GWPH is holding a Zacks Rank of #3 (Hold) right now.
The Medical - Products industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 107, which puts it in the top 42% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
To follow GWPH in the coming trading sessions, be sure to utilize Zacks.com.
Image: Bigstock
GW Pharmaceuticals PLC (GWPH) Stock Moves -1.1%: What You Should Know
GW Pharmaceuticals PLC closed the most recent trading day at $119.53, moving -1.1% from the previous trading session. This change was narrower than the S&P 500's 1.91% loss on the day. Meanwhile, the Dow lost 2.02%, and the Nasdaq, a tech-heavy index, lost 2.26%.
Heading into today, shares of the company had lost 7.27% over the past month, lagging the Medical sector's gain of 0.32% and the S&P 500's loss of 2.51% in that time.
GWPH will be looking to display strength as it nears its next earnings release, which is expected to be February 4, 2019. The company is expected to report EPS of -$2.82, down 16.05% from the prior-year quarter. Our most recent consensus estimate is calling for quarterly revenue of $13.30 million, up 72.06% from the year-ago period.
GWPH's full-year Zacks Consensus Estimates are calling for earnings of -$9.41 per share and revenue of $115.39 million. These results would represent year-over-year changes of +10.89% and +580.53%, respectively.
Investors might also notice recent changes to analyst estimates for GWPH. These revisions help to show the ever-changing nature of near-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the company's business outlook.
Our research shows that these estimate changes are directly correlated with near-term stock prices. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Within the past 30 days, our consensus EPS projection has moved 39.47% lower. GWPH is holding a Zacks Rank of #3 (Hold) right now.
The Medical - Products industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 107, which puts it in the top 42% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
To follow GWPH in the coming trading sessions, be sure to utilize Zacks.com.